Clinical Trial Update: Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole [Phase 4]

View source ↗

Summary

Phase 4 trial update examining adiposity and metabolic measures when switching from atypicals to aripiprazole in schizophrenia patients, with Type 2 diabetes me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Type 2 Diabetes Mellitus

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Schizophrenia, Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2019-01-15